Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases
- 12 November 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (20), e1867-e1872
- https://doi.org/10.1212/wnl.0000000000008479
Abstract
Objective To determine the diagnostic relevance of myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) in CSF of seronegative cases by retrospectively analyzing consecutive time-matched CSF of 80 MOG-Ab–seronegative patients with demyelinating disease. Methods The cohort included 44 patients with NMOSD and related disorders and 36 patients with multiple sclerosis (MS). Two independent neurologists blinded to diagnosis analyzed MOG-Abs by live cell-based immunofluorescence assay with goat anti-human immunoglobulin (Ig) G (whole molecule) antibody. Sera were tested at dilutions of 1:20 and 1:40, and a cutoff of 1:160 was considered for serum positivity. CSF specimens were tested undiluted and at 1:2 dilution with further titrations in case of positivity. Anti-IgG–Fc and anti-IgM-µ secondary antibodies were used to confirm the exclusive presence of MOG-IgG in positive cases. CSF of 13 MOG-Abs seropositive cases and 36 patients with neurodegenerative conditions was analyzed as controls. Results Three seronegative cases had CSF MOG-Abs (4% of the whole cohort or 7% of cases excluding patients with MS, in which MOG-Abs seem to lack diagnostic relevance). In particular, 2 patients with neuromyelitis optica spectrum disorder (NMOSD) and 1 with acute disseminated encephalomyelitis had MOG-Abs in CSF. Analysis with anti-IgG–Fc and anti-IgM confirmed the exclusive presence of MOG-IgG in the CSF of these patients. Among the control group, MOG-Abs were detectable in the CSF of 8 of 13 MOG-Ab–seropositive cases and in none of the patients with neurodegenerative disorders. Conclusion Although serum is the optimal specimen for MOG-Ab testing, analyzing CSF could improve diagnostic sensitivity in seronegative patients. This observation has relevant diagnostic impact and might provide novel insight into the biological mechanisms of MOG-Ab synthesis.Keywords
This publication has 9 references indexed in Scilit:
- Clinical significance of assaying anti-MOG antibody in cerebrospinal fluid in MOG-antibody-associated diseases: A case reportMultiple Sclerosis and Related Disorders, 2019
- Myelin oligodendrocyte glycoprotein antibodies in neurological diseaseNature Reviews Neurology, 2018
- Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter studyZeitschrift für Neurologie, 2017
- MOG-IgG-positive multifocal myelitis with intrathecal IgG synthesis as a spectrum associated with MOG autoimmunity: Two case reportsJournal of the Neurological Sciences, 2017
- ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reportsNeurology Neuroimmunology & Neuroinflammation, 2017
- Case of steroid‐responsive unilateral encephalitis with anti‐myelin oligodendrocyte glycoprotein antibodiesNeurology and Clinical Neuroscience, 2017
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and originJournal of Neuroinflammation, 2016
- Clinical utility of testing AQP4-IgG in CSFNeurology Neuroimmunology & Neuroinflammation, 2016
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015